Please try another search
Lucid Diagnostics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 1 million compared to USD 0.446 million a year ago. Net loss was USD 10.61 million compared to USD 16.25 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.4 a year ago. Diluted loss per share from continuing operations was USD 0.4 compared to USD 0.4 a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 1 | 1.04 | 0.783 | 0.159 |
Gross Profit | -0.655 | -0.417 | -0.851 | -1.39 |
Operating Income | -10.79 | -11.45 | -11.13 | -11.58 |
Net Income | -10.61 | -10.83 | -14.21 | -11.38 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 32.05 | 27.27 | 33.24 | 42.49 |
Total Liabilities | 20.15 | 29.58 | 30.69 | 27.42 |
Total Equity | 11.89 | -2.31 | 2.56 | 15.07 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -12.61 | -9.98 | -8.78 | -7.01 |
Cash From Investing Activities | -0.037 | -0.175 | -0.014 | -0.015 |
Cash From Financing Activities | 18.52 | 5 | 0.275 | 0.075 |
Net Change in Cash | 5.87 | -5.15 | -8.52 | -6.95 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review